BoHV-1 gG-/tk- 基因缺失疫苗的免疫原性增强
本研究在中国用流行野型BoHV-1株攻击免疫牛,比较gG-/tk-双基因缺失疫苗与市售灭活疫苗。免疫后所有牛直肠温度正常且无呼吸道症状,基因缺失疫苗组IFN-γ和TNF-α表达显著升高。攻毒后免疫组产生高水平中和抗体和特异性gB抗体,排毒量显著低于未免疫攻毒组,肺组织结构更完整,基于临床症状和肺病变平均评分的保护率更高。
要点
- gG-/tk-基因缺失疫苗接种牛后IFN-γ和TNF-α表达显著增加。
- 攻毒后免疫组排毒量显著低于未免疫攻毒组,肺结构更完整。
- gG-/tk-疫苗基于临床症状和肺病变平均评分的保护率高于其他受试疫苗。
核心结论
- BoHV-1 gG-/tk-基因缺失疫苗提供强保护且免疫原性优于现有灭活疫苗,具有未来市场应用潜力。
研究设计与样本
- 研究用流行野型BoHV-1株攻击已免疫牛,并将gG-/tk-双基因缺失疫苗与市售灭活BoHV-1疫苗进行比较。
主要发现
- 免疫后所有牛维持正常直肠温度且无呼吸道症状。
- 接种基因缺失疫苗的牛IFN-γ和TNF-α表达显著增加。
- 攻毒后所有免疫组产生高水平中和抗体和特异性gB抗体。
- 免疫组病毒排毒量显著低于未免疫攻毒组。
- 攻毒后接种疫苗犊牛肺组织结构较未免疫 counterparts 更完整。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bovine herpesvirus type 1 (BoHV-1) is a widespread respiratory infection that significantly impacts cattle health worldwide. To address this issue in China, we previously developed a novel double gene-deleted vaccine targeting gG and tk. In this study, we further evaluated the efficacy of this vaccine by challenging vaccinated cattle with a prevalent wild-type BoHV-1 strain and comparing its effectiveness against a commercially available inactivated BoHV-1 vaccine. Post-immunization, all cattle maintained normal rectal temperatures and exhibited no respiratory symptoms. Cattle receiving the gene-deleted vaccine showed a significant increase in the expression of immune markers IFN-γ and TNF-α. Following exposure to wild-type BoHV-1, all immunized groups produced high levels of neutralizing antibodies and specific gB antibodies. Notably, virus shedding was significantly lower in the vaccinated groups compared to the non-immune challenge group. Histological analysis of lung tissues revealed that vaccinated calves had more intact lung structure than their unimmunized counterparts after the challenge. Additionally, the gG-/tk- gene-deleted vaccine demonstrated a higher protective rate based on the average scores of clinical symptoms and lung lesions. Overall, the BoHV-1 gG-/tk- gene-deleted vaccine outperformed the other vaccines tested. This study confirms that the gene-deleted vaccine provides robust protection and superior immunogenicity compared to existing inactivated vaccines, underscoring its potential for future market application.
引用
- Zhang S, Liu G, Wang C, et al. Enhanced immunogenicity of a BoHV-1 gG-/tk- vaccine. Vaccine. 2025. PMID: 39778477. doi:10.1016/j.vaccine.2025.126704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。